Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Specialists’ call on MEP’s to improve childhood cancer treatment

29.10.2004


Europe should take all possible measures to enhance the existing collaboration between paediatric oncologists, both in the treatment and research of childhood cancers. Paediatric oncologists are concerned that current and proposed EU legislations could jeopardise this collaboration and, as a consequence, could impact on the provision of optimal treatment for children with cancer. This was the warning given at a Lunch Debate at the European Parliament in Strasbourg, France (on Wednesday 27th October) organised jointly by Dr. Peter Liese, MEP, and the Federation of European Cancer Societies (FECS) and its society of paediatric oncologists (SIOPE).



“As cancers in young people are relatively rare, treatment requires a particular concentration of resources and expertise at EU level”, explained Prof. Michael Stevens of SIOPE. This is why paediatric oncologists have a long tradition of collaborating both in aspects of cancer care as well as in academic clinical research. However, they urgently need the support of the EU decision-makers to be able to continue this absolutely essential collaborative approach. Addressing an audience of MEP’s, European Commission officials, health professionals and journalists, Prof. Stevens described how, “although cancer under 18 years of age may be relatively rare, it is still the most common medical cause of death after the first year of life and occurs at a rate of about 175 cases per million young people (aged less than 18 years) each year and, cumulatively, the individual risk approaches 1:500 by the age of 18.” “For countries where the best survival rates of approximately 70% can be achieved, 1:700 young adults is a survivor of childhood cancer”. “Nevertheless, it is important to recognize that whilst there was, approximately, a 50% reduction in mortality in the years from 1970 - 1990, there has been a further reduction in mortality of only about 2% in the past 10 years”.

As a consequence of its low incidence and its unique biology, childhood cancers provide very different challenges to doctors and carers involved in treating the disease. However, with optimal treatment, significantly higher cure rates can be achieved in children than can be achieved for most forms of adult cancer. “To enable these cure rates to be widely achieved across Europe (rather than in a few countries only, as is presently the case) there need to be urgent changes made to a range of issues that currently hold back the progress of delivery of quality treatment for paediatric cancer across the entire European Union”, explained Prof. Stevens.


Three main areas where changes to legislation could lead to improved survival rates for children suffering from cancer have been identified:

1) Most of the drugs used to treat paediatric cancers do not have a licence for paediatric use and are out of patent. Clinical trials to establish valid safety and dose/schedule data for these existing drugs are of crucial importance. The current proposed regulation on “paediatric medicines” (adopted by the Commission in September 2004: http://pharmacos.eudra.org/F2/home/.html) is very much welcomed but focuses very much on products covered by a patent or a SPC but doesn’t foresee enough support for out of patent drugs and for academic research aimed at identifying the best therapeutic protocol. The EU urgently needs to allocate financial support to this type of research.

2) The enormous challenges raised by the EU Clinical Trials Directive, which doesn’t properly take into account the specificities, and the relevance to public health, of academic clinical research, jeopardise the future work of the already established network of paediatric oncologists involved in international collaborative clinical trials. MEP’s should raise, in their countries, the problems the Clinical Trials Directive will cause for academic clinical research and, if necessary, consider the need to re-open the Directive.

3) Improving collaboration between paediatric oncologists should also be addressed by suggesting changes to the structural organisation of care in Member States. This would lead to optimal treatments and better outcomes across Europe. Paediatric oncology experts recommend that the European Parliament includes in its resolution about the European Commission’s communication on “Patients’ mobility”, the concept of a feasibility study on “shared care” by which a “centre of reference” is responsible for diagnosis, treatment planning and some aspects of treatment delivery but where other aspects of care are delivered closer to home, under the guidance of the ’centre of reference’ and according to well established standard protocols, supported by robust staff education programmes and delivered in partnership with parents and carers.

Mrs. Marianne Naafs-Wilstra, speaking on behalf of the International Confederation of Childhood Cancer Parent Organisations (ICCCPO), endorsed these calls for action. “ Politicians should strive to ensure that all children with cancer receive the same diagnostic and therapeutic possibilities, and the same level of care, as is currently received by only a minority of children in the EU”.

“Immediate action to tackle these three areas is of paramount importance to improve the outlook for children with cancer all across Europe”, added Prof. Stevens. “The Federation of European Cancer Societies, ICCCPO and paediatric oncologists across Europe (through SIOPE) are united in asking for these concerns to be addressed at the highest level”.

Dr Stuart Bell | alfa
Further information:
http://www.fecs.be

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>